The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO)

The aim of this study was to describe the initial 3-year experience in vein-to-vein time for axi-cel therapy and the role of pharmacists in the first recruiting French centers. Retrospective observational data were collected for vein-to-vein time for commercial axi-cel after ≥ 2 lines of systemic therapy between January 2019 and December 2021 in the first 12 authorized French centers. Hospital pharmacists used a circuit database to ensure the prospective traceability at all steps. Totally 501 of the 562 intention-to-treat registrations on the database for cytapheresis (89,1%) led to the infusion of axi-cel. Median vein-to-vein time was shortened by 4 days. This was mainly due to tightening the interval from apheresis to release. The 36-day median vein-to-vein time achieved after 3 years' experience should be compared to the 29-34 days reported in Canada, the USA and Israel, where manufacturing sites are geographically closer to hospital centers than they are in France. The top 5 recruiting centers had the shortest vein-to-vein times. This French experience may serve as a model for other European centers, notably as regards deployment of pharmacists to improve the patient pathway with CAR T-cells and other gene and cellular therapies.

Authors

Institutions

Publication Details

Journal
Hematological Oncology
Published
2025-10-22
DOI
https://doi.org/10.1002/hon.70144
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO)

Florence Ranchon, Isabelle Madelaine‐Chambrin, Benjamin Sourisseau, Vérane Schwiertz et al.
Hematological Oncology
CAR-T cell therapy research
article

The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO)

Florence Ranchon, Isabelle Madelaine‐Chambrin, Benjamin Sourisseau, Vérane Schwiertz, Romain de Jorna, Marine Pinturaud, Pauline Gueneau, Catherine Rioufol, Emmanuelle Fougereau, Mathieu Wasiak, Muriel Paul, R. Chevrier, Adeline Quintard, Bertrand Pourroy, Élise D’Huart, Muriel Carvalho, Nicolas Cormier, Jean‐Louis Cazin, Marie‐Antoinette Lester, Alexia Jouvance
article en

Abstract

The aim of this study was to describe the initial 3-year experience in vein-to-vein time for axi-cel therapy and the role of pharmacists in the first recruiting French centers. Retrospective observational data were collected for vein-to-vein time for commercial axi-cel after ≥ 2 lines of systemic therapy between January 2019 and December 2021 in the first 12 authorized French centers. Hospital pharmacists used a circuit database to ensure the prospective traceability at all steps. Totally 501 of the 562 intention-to-treat registrations on the database for cytapheresis (89,1%) led to the infusion of axi-cel. Median vein-to-vein time was shortened by 4 days. This was mainly due to tightening the interval from apheresis to release. The 36-day median vein-to-vein time achieved after 3 years' experience should be compared to the 29-34 days reported in Canada, the USA and Israel, where manufacturing sites are geographically closer to hospital centers than they are in France. The top 5 recruiting centers had the shortest vein-to-vein times. This French experience may serve as a model for other European centers, notably as regards deployment of pharmacists to improve the patient pathway with CAR T-cells and other gene and cellular therapies.

Hematological OncologyVol. 43(6)
Université Claude Bernard Lyon 1 (FR), Université de Lille (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Centre Hospitalier Universitaire de Lille (FR), Centre Hospitalier Universitaire de Nantes (FR), Assistance Publique Hôpitaux de Marseille (FR), Centre Hospitalier Universitaire de Montpellier (FR), Centre Hospitalier Régional et Universitaire de Nancy (FR), Hospices Civils de Lyon (FR), Centre d’Investigation Clinique Innovation Technologique de Nancy (FR), CHU Dijon Bourgogne (FR), Centre Jean Perrin (FR), Centre d'Investigation Clinique de Nantes (FR), Société Française d'Allergologie (FR), Centre Hospitalier Universitaire de Clermont-Ferrand (FR), Hôpitaux Universitaires Henri-Mondor (FR), Société Française de Cardiologie (FR), Hôpital Saint-Louis (FR), Institut Paoli-Calmettes (FR), Centre Hospitalier Universitaire de Rennes (FR), Institut de Biologie de Lille (FR), Université Lille Nord de France (FR)
Openalex Percentile: Top 59%
CAR-T cell therapy research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.